Melanoma | Tumor

First Patient Dosed in Trial of [212Pb]VMT01 for Metastatic Melanoma

March 30th 2025, 6:00pm

Article

The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with melanoma.

Solnerstotug Demonstrates Early Efficacy in PD-L1 Resistant Tumors

March 28th 2025, 3:00pm

Article

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.

How Subcutaneous vs IV May Affect Treatment Adherence in Cancer Care

January 27th 2025, 2:00pm

Article

Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version for patients with solid tumors.

The FDA Accepts a BLA for RP1 Plus Opdivo in Advanced Melanoma

January 23rd 2025, 4:00pm

Article

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have progressed on prior therapy.

The Significance of the Subcutaneous Opdivo FDA Approval in Solid Tumors

January 20th 2025, 2:00pm

Article

Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means for those with solid tumors.

The Subcutaneous Approval of Opdivo Makes Waves in Future of Cancer Care

January 15th 2025, 10:00pm

Article

Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient access, according to experts.

Understanding the Benefit of Subcutaneous Versus IV Opdivo in Patients With Solid Tumors

January 8th 2025, 8:00pm

Article

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors.

Top 5 Cancer Vaccine Stories from 2024

December 25th 2024, 3:00pm

Article

With breakthroughs from melanoma to pancreatic cancer, this has been a year of great promise in the field of cancer vaccines.

NFL Star Randy Moss Undergoing Cancer Treatment, Montell Jordan Shares Update and More

December 20th 2024, 4:00pm

Article

From a Pro Football Hall of Famer announcing his diagnosis to an R&B star’s latest update, here’s what’s happening in the cancer space this week.

First Patient Enrolled Receives Kimmtrak in Phase 3 Uveal Melanoma Trial

December 16th 2024, 10:00pm

Article

The first patient was enrolled in a phase 3 trial for patients with non-metastatic uveal melanoma to either receive Kimmtrak or observation.